First it was chemotherapy. Then came targeted therapies. Now, immunotherapies are all the rage. Did you know that each of these therapeutic approaches is negatively impacted by obesity and metabolic dysfunction? The next major advancement in cancer treatment is metabo-oncology, the area of research dedicated to understanding and treating cancer patients with obesity and metabolic dysfunction. This common co-morbidity centers on hyperadiposity (visceral fat) and metabolic dysfunction (e.g. insulin resistance, high leptin levels and chronic inflammation) which accelerate cancer growth and metastasis and protect cancer cells from immunosurveillance and many forms of treatment.